Treatment Groups and Interventions for a U.S. Acute Rhinosinusitis Clinical Trial

A 2026 protocol dataset from a large, multi-center, pragmatic randomized controlled trial evaluating antibiotic and non-antibiotic treatments for Acute Rhinosinusitis (ARS). The trial, authored by Daniel Merenstein, is designed to enroll 3,720 participants across primary and urgent care settings in six U.S. regions. It compares four treatment strategies for participants whose symptoms persist after initial care.

Use Cases

• Analyze the comparative effectiveness of antibiotics versus intranasal corticosteroids based on the described four-arm trial design.
• Study patient subgroups most likely to benefit from specific therapies based on the trial's objective to identify clinical and laboratory indicators.
• Model healthcare cost implications for ARS based on the description of its significant economic burden.
• Design similar pragmatic trials in primary care settings based on the described methodology and scale.

Strengths

• Describes a large-scale trial with a planned enrollment of 3,720 participants.
• Provides a clear, placebo-controlled, four-group randomized design for rigorous comparison.
• Focuses on a high-burden condition, citing ARS affects 15% of adults annually and contributes to over $11 billion in U.S. healthcare costs.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (5.5 KB), suggesting it contains summary protocol information rather than detailed participant-level data.

Provenance

Source

Daniel Merenstein via figshare.

Collection Method

Protocol for a randomized controlled trial.

Time Range

Trial is underway as of the 2026 protocol date.

Freshness

Last updated 2026-05-06 17:29:11; freshness should be verified.

Geography

Six regions across the United States.